NCT02842242

A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: MyoKardia, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this phase 2 open-label pilot study is to evaluate the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of MYK-461 in subjects with symptomatic HCM and LVOT obstruction aged 18-70 years.

Conditions

• Cardiomyopathy, Hypertrophic Obstructive
• Left Ventricular Outflow Tract Obstruction

Interventions

Type	Name	Description
DRUG	MYK-461

Timeline

• Start date: 2016-08-01
• Primary completion: 2017-11-01
• Completion: 2017-11-01
• First posted: 2016-07-22
• Last updated: 2021-06-08
• Results posted: 2020-02-05

Locations

7 sites across 1 country: United States